Therapy Areas: Cardiovascular
Canopy Biosciences acquires the exclusive license to the Error Corrected Sequencing Technology
6 March 2019 -

Gene editing company Canopy Biosciences LLC reported on Wednesday the launch of an agreement to exclusively license the technology for error correction in next generation sequencing (NGS) from Washington University.

The company added that the Error Corrected Sequencing Technology license includes both a novel method and bioinformatic tools that combine to significantly improve the level of detection in NGS, allowing for the identification of ultra-rare gene variants in the clinical space. Todd Druley, MD PhD is the coinventor of the technology.

NGS' Error Corrected Sequencing Technology, which was developed as an ultra-sensitive method to detect residual disease in paediatric leukemia, utilises unique molecular index (UMI) technology to help differentiate rare genetic events from errors that may have occurred in the sequencing workflow,breakthrough for the clinical space.

In fact, the research using this NGS technology has already unveiled gene variants that have been validated and have impacted in ageing, cardiovascular disease and cancer, revealed the company.

The company added that it expects to launch a service based on this license by the the second quarter of 2019, as well as continue to build on its solid foundation of CRO services, including RNAseq, NanoString and Meso Scale Discovery, to provide cutting edge and powerful tools to the research community.

Login
Username:

Password: